Alice Dragomir
Associate Professor
MSc PhD
FRQS Chercheur boursier Junior 2
Health economics and outcomes research in Uro-Oncology
Dr. Dragomir is an health economist and biostatistician with master degree in statistics and doctoral degree in pharmacoepidemiology and pharmacoeconomics, from University of Montreal, Canada. She has 19 years of experience in academic research. She was involved in research projects focused on evaluation of health outcomes and health economics related to different treatment strategies, adherence to treatments, health services utilization and disease modeling in several fields, such as: hypertension, dyslipidemia, cardiovascular diseases, osteoporosis, mental health diseases, and cancers. Her current research is focused on clinical and economic evaluation of different treatments strategies offered to patients with urological cancers. She has an extended experience in conducting studies based on administrative healthcare databases, such as RAMQ and Med-Echo, and conducting economic evaluation. Her research represents a valuable tool for decision-makers and clinician leaders when evaluating the clinical and economic impacts of innovative treatments.
*student supervised by Dr Dragomir
1: El-Haouly A*, Lacasse A, El-Rami H, Liandier F, Dragomir A. Out-of-Pocket Costs and Perceived Financial Burden Associated with Prostate Cancer Treatment in a Quebec Remote Area: A Cross-Sectional Study. Curr Oncol. 2020 Nov 30;28(1):26-39. doi: 10.3390/curroncol28010005. PMID: 33704114; PMCID: PMC7816191.
2: Wissing MD, O'Flaherty A, Dragomir A, Tanguay S, Kassouf W, Aprikian AG. The Use of 5-Alpha Reductase Inhibitors and Alpha-1 Blockers Does Not Improve Clinical Outcome in Male Patients Undergoing Radical Cystectomy for Bladder Cancer in Quebec, Canada. Clin Genitourin Cancer. 2021 Feb 6:S1558-7673(21)00030-6. doi: 10.1016/j.clgc.2021.01.007. Epub ahead of print. PMID: 33676834.
3: Perreault S, Dragomir A, C么t茅 R, Lenglet A, White-Guay B, de Denus S, Schnitzer ME, Dub茅 MP, Brophy JM, Dorais M, Tardif JC. Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study. Pharmacotherapy. 2021 Apr;41(4):379-393. doi: 10.1002/phar.2509. Epub 2021 Feb 27. PMID: 33544915.
4: Hu J*, Aprikian AG, Vanhuyse M, Dragomir A. Contemporary Population-Based Analysis of Bone Mineral Density Testing in Men Initiating Androgen Deprivation Therapy for Prostate Cancer. J Natl Compr Canc Netw. 2020 Oct 1;18(10):1374-1381. doi: 10.6004/jnccn.2020.7576. PMID: 33022649.
5: El-Haouly A*, Dragomir A, El-Rami H, Liandier F, Lacasse A. Treatment decision-making in men with localized prostate cancer living in a remote area: A cross-sectional, observational study. Can Urol Assoc J. 2021 Mar;15(3):E160-E168. doi: 10.5489/cuaj.6521. PMID: 32807284; PMCID: PMC7943242.
6: Dragomir A, Nazha S*, Wood LA, Rendon RA, Finelli A, Hansen A, So AI, Kollmannsberger C, Basappa NS, Pouliot F, Souli猫res D, Heng DYC, Kapoor A, Tanguay S. Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience. Urol Oncol. 2020 Oct;38(10):799.e1-799.e10. doi: 10.1016/j.urolonc.2020.07.021. Epub 2020 Aug 7. PMID: 32778475.
7: Hu J*, Aprikian AG, Vanhuyse M, Dragomir A. Cancer Drug Use in the Last Month of Life in Men With Castration-Resistant Prostate Cancer. J Oncol Pract. 2019 Jun;15(6):e510-e519. doi: 10.1200/JOP.18.00626. Epub 2019 May 20. PMID: 31107628.
8: Lahcene H*, Aprikian AG, Vanhuyse M, Hu J*, Bladou F, Cury F, Kassouf W, Perreault S, Dragomir A. Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice. J Oncol Pharm Pract. 2020 Mar;26(2):293-305. doi: 10.1177/1078155219842329. Epub 2019 Apr 18. PMID: 30997868.
9: Olleik G*, Kassouf W, Aprikian A, Hu J*, Vanhuyse M, Cury F, Peacock S, Bonnevier E*, Palenius E*, Dragomir A. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review. J Natl Compr Canc Netw. 2018 Nov;16(11):1340-1351. doi: 10.6004/jnccn.2018.7055. PMID: 30442734.
10: Nazha S*, Tanguay S, Kapoor A, Jewett M, Kollmannsberger C, Wood L, Bjarnason GAG, Heng D, Souli猫res D, Reaume MN, Basappa N, L茅vesque E, Dragomir A. Cost- utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence. Clin Drug Investig. 2018 Dec;38(12):1155-1165. doi: 10.1007/s40261-018-0705-6. PMID: 30267257.
11: Zakaria AS, Dragomir A, Brimo F, Kassouf W, Tanguay S, Aprikian A. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening. BMC Urol. 2018 Aug 20;18(1):69. doi: 10.1186/s12894-018-0384-x. PMID: 30126402; PMCID: PMC6102901.
12: Shamout S*, Nazha S*, Dragomir A, Campeau L. A cost-utility analysis of artificial urinary sphincter versus AdVance male sling in post prostatectomy stress urinary incontinence: A publicly funded health care perspective. Neurourol Urodyn. 2018 Sep;37(7):2195-2203. doi: 10.1002/nau.23559. Epub 2018 Apr 10. PMID: 29635704.
13: Dragomir A, Aprikian A, Kapoor A, Finelli A, Pouliot F, Rendon R, Black PC, Moore R, Breau RH, Kawakami J, Drachenberg D, Lattouf JB, Tanguay S. Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study. CMAJ Open. 2017 Dec 11;5(4):E834-E841. doi: 10.9778/cmajo.20170005. PMID: 29229610; PMCID: PMC5741415.